miRNA | signaling pathways | target genes | source | characteristic BC features | references |
---|---|---|---|---|---|
miR-21 | apoptosis; EGFR | PDCD4, PTEN, BCL-2, HER2, FAS, TPM1 | serum | ↗ in primary BC, correlation to tumor size and lymph node status | |
miR-34 a | vascularization; EGFR, β-Catenin | VEGF, MYC, BCL2, WNT, p53 | serum | ↗ in metastatic BC compared to primary BC and controls | |
miR-125b | apoptosis; EGFR | HER2, p53, BAK1 | serum | ↗ in primary BC, prediction of chemotherapy resistance | |
miR-155 | Akt; apoptosis; morphogenesis; EMT | VHL, VEGF, p53, TGF- β | serum | ↗ in primary BC; ↘ after surgery and chemotherapy | |
miR-195 | apoptosis | BCL 2, CDK6 | whole blood | ↗ in primary BC | |
serum | ↘ in primary BC | [22] | |||
miR-200b | EMT | ZEB1/2, E-Cadherin | plasma | ↗ in metastatic BC; correlation to CTC status | |
miR-200c | EMT | ZEB1/2, E-Cadherin | plasma | ↗ in metastatic BC; correlation to CTC status | |
miR-375 | apoptosis | 14-3-3 Protein | plasma | ↗ in metastatic BC | |
miR-451 | MDR | MDR1, 14-3-3 Protein | plasma, serum | ↗ in primary BC |